The latest global burden of liver cancer: A past and present threat.
作者信息
Oh Joo Hyun, Jun Dae Won
机构信息
Department of Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
Department of Medicine, Hanyang University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2023 Apr;29(2):355-357. doi: 10.3350/cmh.2023.0070. Epub 2023 Mar 9.
Abstract
摘要
相似文献
1
The latest global burden of liver cancer: A past and present threat.最新的全球肝癌负担：过去与现在的威胁。
Clin Mol Hepatol. 2023 Apr;29(2):355-357. doi: 10.3350/cmh.2023.0070. Epub 2023 Mar 9.
2
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.2015 年全球疾病负担研究：1990 年至 2015 年全球、区域和国家一级原发性肝癌及相关病因负担。
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. doi: 10.1001/jamaoncol.2017.3055.
3
The current trends in the health burden of primary liver cancer across the globe.全球原发性肝癌健康负担的当前趋势。
Clin Mol Hepatol. 2023 Apr;29(2):358-362. doi: 10.3350/cmh.2023.0092. Epub 2023 Mar 14.
4
The global burden of peripheral artery disease.外周动脉疾病的全球负担。
J Vasc Surg. 2023 Apr;77(4):1119-1126.e1. doi: 10.1016/j.jvs.2022.12.015. Epub 2022 Dec 21.
5
Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019.全球疾病负担 1990-2019 年肝癌病因全球、区域和国家负担及护理质量指数趋势。
Hepatol Commun. 2022 Jul;6(7):1764-1775. doi: 10.1002/hep4.1910. Epub 2022 Feb 8.
6
The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels.2019 年全球、区域和国家层面由特定病因导致的原发性肝癌负担。
Cancer Med. 2022 Mar;11(5):1357-1370. doi: 10.1002/cam4.4530. Epub 2022 Jan 6.
7
[Estimation on disease burden related to hepatitis B virus infection in Shandong province of China].[中国山东省乙型肝炎病毒感染相关疾病负担估计]
Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Jul;30(7):679-83.
8
Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases.1997年至2016年中国肝癌的疾病负担：一项基于全球疾病负担的观察性研究
BMJ Open. 2019 Apr 23;9(4):e025613. doi: 10.1136/bmjopen-2018-025613.
9
Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021.全球心血管疾病负担与风险协作组，1990 - 2021年。
J Am Coll Cardiol. 2022 Dec 20;80(25):2372-2425. doi: 10.1016/j.jacc.2022.11.001.
10
Correspondence on 'Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017'.关于“1990年至2017年全球、区域和国家层面五种常见肌肉骨骼疾病的发病趋势：全球疾病负担研究2017的结果”的通信
Ann Rheum Dis. 2023 Feb;82(2):e46. doi: 10.1136/annrheumdis-2020-219522. Epub 2020 Dec 2.
引用本文的文献
1
Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.慢性丁型肝炎中的宿主免疫反应：对发病机制和治疗的影响
Pathogens. 2025 Aug 21;14(8):828. doi: 10.3390/pathogens14080828.
2
Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study.1990年至2021年欧洲地区肝癌负担：全球疾病负担研究的子分析
Ann Med Surg (Lond). 2025 May 30;87(7):4053-4065. doi: 10.1097/MS9.0000000000003433. eCollection 2025 Jul.
3
Primary Hepatocellular Carcinoma Developing Within a B-cell Primary Hepatic Lymphoma in a Hepatitis C Positive Patient.丙型肝炎阳性患者的B细胞原发性肝淋巴瘤内发生的原发性肝细胞癌
Cureus. 2025 Jul 18;17(7):e88274. doi: 10.7759/cureus.88274. eCollection 2025 Jul.
4
ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma.ZEB1对肝细胞癌中索拉非尼和Mdivi-1联合治疗的反应进行分层。
Sci Rep. 2025 Aug 19;15(1):30451. doi: 10.1038/s41598-025-16379-6.
5
Primary liver cancer burden and its association with health development in the Western Pacific, 1990-2021.1990 - 2021年西太平洋地区原发性肝癌负担及其与健康发展的关联
Front Oncol. 2025 Jul 31;15:1627330. doi: 10.3389/fonc.2025.1627330. eCollection 2025.
6
Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer.丙氨酸分解代谢作为MYC驱动的肝癌的一个可靶向的脆弱点。
bioRxiv. 2025 Aug 12:2025.07.29.667471. doi: 10.1101/2025.07.29.667471.
7
Role of Liquid Biopsy for Early Detection, Prognosis, and Therapeutic Monitoring of Hepatocellular Carcinoma.液体活检在肝细胞癌早期检测、预后评估及治疗监测中的作用
Diagnostics (Basel). 2025 Jun 28;15(13):1655. doi: 10.3390/diagnostics15131655.
8
DynTransNet: Dynamic Transformer Network with multi-scale attention for liver cancer segmentation.DynTransNet：用于肝癌分割的具有多尺度注意力的动态变压器网络。
Front Oncol. 2025 Jun 19;15:1569083. doi: 10.3389/fonc.2025.1569083. eCollection 2025.
9
Imiquimod-Loaded Phospholipid-Free Small Unilamellar Vesicles Activate the Tumor Immune Microenvironment to Treat Liver Cancer and Liver Metastases.负载咪喹莫特的无磷脂小单层囊泡激活肿瘤免疫微环境以治疗肝癌和肝转移
Adv Healthc Mater. 2025 Aug;14(22):e2501691. doi: 10.1002/adhm.202501691. Epub 2025 Jun 17.
10
Effectiveness of herbal medicine for liver cancer treatment as revealed by a bibliometric and visualization analysis.文献计量学与可视化分析揭示的草药治疗肝癌的有效性
Front Oncol. 2025 May 8;15:1527091. doi: 10.3389/fonc.2025.1527091. eCollection 2025.
本文引用的文献
1
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.全球原发性肝癌负担及其与潜在病因、社会人口地位和性别差异的关系：基于残疾调整生命年的 2019 年全球疾病负担研究分析。
Clin Mol Hepatol. 2023 Apr;29(2):433-452. doi: 10.3350/cmh.2022.0316. Epub 2023 Jan 4.
2
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.
3
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肝细胞癌监测。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S207-S219. doi: 10.3350/cmh.2022.0247. Epub 2022 Sep 14.
4
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly.韩国的肝细胞癌发病率正在下降，但在非常老年人群中却在上升。
Clin Mol Hepatol. 2023 Jan;29(1):120-134. doi: 10.3350/cmh.2021.0395. Epub 2022 Aug 12.
5
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review.全球各国、各地区及全球范围内肝硬化患者中乙型肝炎病毒和丙型肝炎病毒的流行情况：系统评价。
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):724-735. doi: 10.1016/S2468-1253(22)00050-4. Epub 2022 May 14.
6
Selecting the Target Population for Screening of Hepatic Fibrosis in Primary Care Centers in Korea.韩国基层医疗中心肝纤维化筛查目标人群的选择
J Clin Med. 2022 Mar 8;11(6):1474. doi: 10.3390/jcm11061474.
7
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.实现慢性乙型肝炎的完全治愈：乙型肝炎病毒的新治疗靶点。
Clin Mol Hepatol. 2022 Jan;28(1):17-30. doi: 10.3350/cmh.2021.0093. Epub 2021 Jul 20.
8
Hepatocellular carcinoma statistics in South Korea.韩国肝细胞癌统计数据。
Clin Mol Hepatol. 2021 Jul;27(3):512-514. doi: 10.3350/cmh.2021.0171. Epub 2021 Jun 21.
9
Global Burden of 5 Major Types of Gastrointestinal Cancer.全球 5 大常见胃肠道癌症负担
Gastroenterology. 2020 Jul;159(1):335-349.e15. doi: 10.1053/j.gastro.2020.02.068. Epub 2020 Apr 2.
10
The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention.特定病因引起的原发性肝癌发病率趋势：2016 年全球疾病负担研究结果及其对肝癌预防的意义。
J Hepatol. 2019 Apr;70(4):674-683. doi: 10.1016/j.jhep.2018.12.001. Epub 2018 Dec 11.
Zotero 插件